Gainers

• China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday's regular session. The market value of their outstanding shares is at $24.9 million.
• Conexeu Sciences (NASDAQ:CNXU) stock rose 23.85% to $11.77. The market value of their outstanding shares is at $254.2 million.
• Fractyl Health (NASDAQ:GUTS) stock moved upwards by 20.96% to $0.97. The market value of their outstanding shares is at $126.9 million.
• Apollomics (NASDAQ:APLM) stock moved upwards by 18.37% to $18.59. The company's market cap stands at $34.4 million.
• Veradermics (NYSE:MANE) stock moved upwards by 16.95% to $128.85. The market value of their outstanding shares is at $4.6 billion.
• VivoSim Labs (NASDAQ:VIVS) shares moved upwards by 16.55% to $0.97. The company's market cap stands at $2.4 million. As per the press release, Q4 earnings came out yesterday.

Losers

• SANUWAVE Health (NASDAQ:SNWV) shares declined by 36.5% to $7.6 during Wednesday's regular session. The company's market cap stands at $102.8 million.
• Cardiff Oncology (NASDAQ:CRDF) shares decreased by 34.76% to $0.85. The company's market cap stands at $89.5 million.
• Senti Biosciences (NASDAQ:SNTI) shares declined by 29.67% to $0.68. The company's market cap stands at $30.1 million.
• Basel Medical Group (NASDAQ:BMGL) shares declined by 23.69% to $6.2. The market value of their outstanding shares is at $12.7 million.
• AEON Biopharma (AMEX:AEON) stock decreased by 18.87% to $0.29. The market value of their outstanding shares is at $9.3 million.
• Celcuity (NASDAQ:CELC) stock fell 17.62% to $91.49. The market value of their outstanding shares is at $5.4 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.